Sponsors should limit placebo-controlled trials in cancer, FDA says

FDA released draft guidance Thursday to debunk the notion that FDA requires the use of placebo in randomized clinical trials for cancer therapies and clarify its general preference for active controls in such trials.


Read the full 349 word article

User Sign In